Agentix Corp. logo

Agentix Corp.

0001603345

Agentix Biopharma is a clinical-stage biotechnology company focused on developing synthetic agonists, inverse agonists, and antagonists that modulate the endocannabinoid system (ECS) for treating metabolic diseases. They advance therapeutic product candidates in clinical trials and partner with leading research institutions. Their focus is on Type 2 Diabetes, obesity, NAFLD and NASH. ECS-targeted drugs have generated multi-billion dollar revenues annually.

80
Très Fiable
Score de Confiance

Registre Officiel

Numéro de TVA
462876282
Adresse
32932 PACIFIC COAST HIGHWAY, DANA POINT, CA 92629
Codes d'Activité
Biological Products, (No Diagnostic Substances), 2836

Analyse Qualité IA

Industrie
Biotechnology
SSL/HTTPS
Sécurisé
E-mail professionnel
Oui
E-mail de contact
info@agentixcorp.com

🌟 Entreprises similaires de confiance

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Très Fiable

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, États-Unis
Voir le profil

AGENUS INC

AGENUS INC logo
86/100 · Très Fiable

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

3 FORBES ROAD, États-Unis
Voir le profil

Evaxion A/S

Evaxion A/S logo
77/100 · Fiable

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, États-Unis
Voir le profil